retatrutide compounding The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide Peptide Therapy | California

But I think hiding it from your doctor is a bad idea

A qualified healthcare provider should evaluate your medical history, medications, contraindications, and metabolic status before recommending any weight-loss approach

Pick a day and stick with it

Pharmacoepidemiol Drug Saf 31:5560

In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fixed-ratio combination of basal insulin and GLP-1 RA demonstrated significant improvements in blood glucose levels and achievement of glycaemic goals with fewer hypoglycaemic events than with basal insulin alone [216,217,218,219,220]

Emerging evidence demonstrates that GLP-1 receptors are expressed in Type II taste cells, where they modulate sweet sensitivity through the G-gustducin/TRPM5 pathway, and downregulate T1R2/T1R3 expression and ATP release (164, 165)